Page 201 - 2022_03-Haematologica-web

Letters to the Editor
Figure 1. SARS-CoV-2–reactive IFNγ-producing T cells after vaccination. Elispot assays were performed, as previously reported (8). Briefly, PBMCs (in concen- trations adjusted to 2x105 CD3+ T cells per well) were plated in anti-IFNγ–coated Elispot 96-well plates in the presence of overlapping 15-mer peptide pools spanning the sequence of SARS-CoV-2 structural and nonstructural proteins: S (pool S1 spanning the N-terminal part of the protein including the S1-subunit, and pool S2 spanning the C-terminal part), N, M, NS3A, NS7A (JPT, Strassberg, Germany). Spots were counted with an automated ELISPOT reader (AID, Strassberg, Germany). Results were expressed as spot forming cells (SFC) per 106 CD3+ T cells. For each assay, a specific response was considered positive if the SFC number was superior to 3 standard deviations of spot numbers observed in wells without antigens (ranging between 9 and 20 SFC/106 CD3+ T cells).
a T-cell response. This should encourage patients and physicians to maintain a proactive vaccine policy.
Sophie Candon,1,2 Véronique Lémée,3 Emilie Lévêque,4 Pascaline Etancelin,5 Cédric Paquin,5 Marion Carette,1 Nathalie Contentin,6 Victor Bobée,7 Mustafa Alani,6 Nathalie Cardinaël,6 Stéphane Leprêtre,6 Vincent Camus,6 Florian Bouclet,6 Edwige Boulet,8 Anne-Lise Ménard,6 Hélène Lanic,6 Aspasia Stamatoullas,6,9 Emilie Lemasle,6 Louis-Ferdinand Pépin,4 Doriane Richard,4 Sydney Dubois,6 Hervé Tilly,6,9 Alain Dalleac,5 Jean-Christophe Plantier,3 Manuel Etienne10 and Fabrice Jardin.6,9
1Laboratory of Immunology and Biotherapies, Rouen University Hospital, France; 2INSERM U1234, University of Rouen Normandy, Rouen, France; 3Normandie Univ, UNIROUEN, UNICAEN, GRAM 2.0, Rouen University Hospital, Department of Virology, Rouen, France; 4Unit of Clinical Research, Centre Henri Becquerel, Rouen, France; 5Department of Biopathology, Centre Henri Becquerel, Rouen, France; 6Department of Clinical Hematology, Centre Henri Becquerel, Rouen, France; 7Laboratory of Hematology, Rouen University Hospital, France; 8Cliniques universitaires UCL de Mont Godinne, Namur, Belgium; 9INSERM U1245, University of Rouen Normandy, Rouen, France and 10Normandie Univ, UNIROUEN, UNICAEN, GRAM 2.0, Rouen University Hospital, Department of Infectious Diseases, Rouen, France
Correspondence:
FABRICE JARDIN- : fabrice.jardin@chb.unicancer.fr doi:10.3324/haematol.2021.280139
Received: October 2, 2021.
Accepted: November 22, 2021.
Pre-published: December 2, 2021.
Disclosures: no conflicts of interest to disclose.
Contributions: FJ, ME, JCP, SG, HT, LFP and DR designed the trial; VL performed serologic analysis; SG and MC performed Elispot analysis; VB performed cytometry analysis; PE, CP per- formed additional biological analysis and logistical tasks; EL per- formed statistical analysis and collected data; HL, SL, EL, NC, VC, ALM, EB, MA, NC enrolled patients in the trial; FJ, HT, ME, SD and SC wrote the manuscript. All authors approved the final manuscript.
Acknowledgments: the authors thank for their help and technical support: Delphine Robbe, Julie Libraire, Nathalie Breda, Laure Gaillon, Justine Loret, Laure Sulpice and Julie Lamulle.
References
1. Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autol- ogous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250-1260.
2. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42-51.
3. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first- line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331-1344.
4. Yasuda H, Tsukune Y, Watanabe N, et al. Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(11):774-776.
5. Dulery R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non- Hodgkin lymphoma treated with B-cell depleting immunothera- py. Am J Hematol. 2021;96(8):934-944.
6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615.
7. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-1423.
8. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine
haematologica | 2022; 107(3)
757